Tuberculosis  >>  Sutezolid (PNU-100480)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sutezolid (PNU-100480) / Sequella
SUDOCU, NCT03959566: PanACEA Sutezolid Dose-finding and Combination Evaluation

Completed
2b
75
RoW
Sutezolid, PNU-100480, Bedaquiline, Delamanid, Moxifloxacin, BDM, Midazolam oral solution
Michael Hoelscher, European and Developing Countries Clinical Trials Partnership (EDCTP), Sequella, Inc., Radboud University Medical Center, University of California, San Francisco, German Federal Ministry of Education and Research
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
09/22
09/22
NCT01225640: PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Completed
2a
59
RoW
PNU-100480, RHZE, Rifafour, Rimstar
Sequella, Inc.
Tuberculosis
12/11
12/11
NCT05971602: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Recruiting
2
514
RoW
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR)
Bill & Melinda Gates Medical Research Institute, Global Alliance for TB Drug Development, Janssen Pharmaceutica, Otsuka Pharmaceutical Co., Ltd.
Pulmonary Tuberculosis
10/27
10/27

Download Options